Effect of the MTHFR C677T and A1298C Polymorphisms on Survival in Patients With Advanced CKD and ESRD: A Prospective Study

American Journal of Kidney Diseases

Volumn 53, Issue 5, 2009, Pages 779-789

  Jamison, Rex L ^a   Shih, Mei Chiung ^a   Humphries, Donald E ^a   Guarino, Peter D ^a   Kaufman, James S ^a   Goldfarb, David S ^a   Warren, Stuart R ^a   Gaziano, J Michael ^a   Lavori, Philip ^a  

^a NONE

Author keywords

advanced chronic kidney disease; end stage renal disease; Methylenetetrahydrofolate reductase gene polymorphisms

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE; MULTIVITAMIN; PYRIDOXINE;

ADULT; AGED; ALLELE; AMINO ACID BLOOD LEVEL; ARTICLE; BLOOD SAMPLING; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CREATININE CLEARANCE; DIALYSIS; DNA EXTRACTION; DNA POLYMORPHISM; ETHNIC GROUP; FEMALE; GENE AMPLIFICATION; GENE FREQUENCY; GENE MUTATION; GENETIC ASSOCIATION; GENOTYPE; HEART INFARCTION; HOMOCYSTINURIA; HUMAN; KIDNEY FAILURE; LEG AMPUTATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; POLYMERASE CHAIN REACTION; RACE DIFFERENCE; RANDOMIZED CONTROLLED TRIAL; STROKE; SURVIVAL RATE; TREATMENT OUTCOME;

AGED; ALLELES; CAUSE OF DEATH; DNA; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); POLYMERASE CHAIN REACTION; PROGNOSIS; RISK FACTORS; SURVIVAL RATE; TIME FACTORS;

EID: 64749085617     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2008.12.023     Document Type: Article

References (41)

1. Frosst P., Blom H.J., Milos R., et al. A candidate genetic risk factor for vascular disease: A common mutation in methylenetetrahydrofolate reductase. Nat Genet 10 (1995) 111-113
2. Cook R.J. Folate metabolism. In: Carmel R., and Jacobsen D.W. (Eds). Homocysteine in Health and Disease (2001), University Press, Cambridge, UK 113-134
3. Weisberg I.S., Jacques P.F., Selhub J., et al. The 1298A→C polymorphism in methylenetetrahydrofolate reductase (MTHFR): In vitro expression and association with homocysteine. Atherosclerosis 156 (2001) 409-415
4. Wald D.S., Law M., and Morris J.K. Homocysteine and cardiovascular disease: Evidence on causality from a meta-analysis. BMJ 325 (2002) 1202-1206
5. Klerk M., Verhoef P., Clarke R., et al. MTHFR 677C→T polymorphism and risk of coronary heart disease: A meta-analysis. JAMA 288 (2002) 2023-2031
6. Lewis S.J., Ebrahim S., and Davey Smith G. Meta-analysis of MTHFR 677C→T polymorphism and coronary heart disease: Does totality of evidence support causal role for homocysteine and preventive potential of folate?. BMJ 331 (2005) 1053-1058
7. Pereira A.C., Miyakawa A.A., Lopes N.H., et al. Dynamic regulation of MTHFR mRNA expression and C677T genotype modulate mortality in coronary artery disease patients after revascularization. Thromb Res 121 (2007) 25-32
8. Garcia-Pinilla J.M., Espinosa-Caliani S., Jimenez-Navarro M., et al. Influence of 677 C→T polymorphism of methylenetetrahydrofolate reductase on medium-term prognosis after acute coronary syndromes. Tex Heart Inst J 34 (2007) 142-147
9. Bathum L., von Bornemann Hjelmborg J., Christiansen L., et al. Methylenetetrahydrofolate reductase 677C→T and methionine synthase 2756A→G mutations: No impact on survival, cognitive functioning, or cognitive decline in nonagenarians. J Gerontol A Biol Sci Med Sci 62 (2007) 196-201
10. Weisberg I., Tran P., Christensen B., et al. A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. Mol Genet Metab 64 (1998) 169-172
11. Kolling K., Ndrepepa G., Koch W., et al. Methylenetetrahydrofolate reductase gene C677T and A1298C polymorphisms, plasma homocysteine, folate, and vitamin B12 levels and the extent of coronary artery disease. Am J Cardiol 93 (2004) 1201-1206
12. Martin D.N., Boersma B.J., Howe T.M., et al. Association of MTHFR gene polymorphisms with breast cancer survival. BMC Cancer 6 (2006) 257
13. Fodinger M., Mannhalter C., Wolfl G., et al. Mutation (677 C to T) in the methylenetetrahydrofolate reductase gene aggravates hyperhomocysteinemia in hemodialysis patients. Kidney Int 52 (1997) 517-523
14. Pernod G., Bosson J.L., Golshayan D., et al. Phenotypic and genotypic risk factors for cardiovascular events in an incident dialysis cohort. Kidney Int 69 (2006) 1424-1430
15. Wrone E.M., Zehnder J.L., Hornberger J.M., et al. An MTHFR variant, homocysteine, and cardiovascular comorbidity in renal disease. Kidney Int 60 (2001) 1106-1113
16. Fletcher O., and Kessling A.M. MTHFR association with arteriosclerotic vascular disease?. Hum Genet 103 (1998) 11-21
17. Aucella F., Margaglione M., Grandone E., et al. The C677T methylenetetrahydrofolate reductase gene mutation does not influence cardiovascular risk in the dialysis population: Results of a multicentre prospective study. Nephrol Dial Transplant 20 (2005) 382-386
18. Kimura H., Gejyo F., Suzuki S., et al. The C677T methylenetetrahydrofolate reductase gene mutation in hemodialysis patients. J Am Soc Nephrol 11 (2000) 885-893
19. Jamison R.L., Hartigan P., Kaufman J.S., et al. Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: A randomized controlled trial. JAMA 298 (2007) 1163-1170
20. Yi P., Pogribny I., and Jill James S. Multiplex PCR for simultaneous detection of 677 C→T and 1298 A→C polymorphisms in methylenetetrahydrofolate reductase gene for population studies of cancer risk. Cancer Lett 181 (2002) 209-213
21. Hougaard P. Analysis of Multivariate Survival Data (2000), Springer, New York, NY 72-73 84-85
22. Therneau T., and Grambsch P. Modeling Survival Data: Extending the Cox Model. (ed 1) (2000), Springer, New York, NY
23. Thomson P.C., Stirling C.M., Geddes C.C., et al. Vascular access in haemodialysis patients: A modifiable risk factor for bacteraemia and death. QJM 100 (2007) 415-422
24. McCully K.S. Vascular pathology of homocysteinemia: Implications for the pathogenesis of arteriosclerosis. Am J Pathol 56 (1969) 111-128
25. Mudd S.H., Levy H.L., and Skovby F. Disorders of transsulfuration. In: Crever C.R., Beaudet A.L., Sly W.S., and Valle D. (Eds). The Metabolic Basis of Inherited Disease. (ed 7) (1994), McGraw-Hill, New York, NY 1279-1327
26. Boushey C.J., Beresford S.A., Omenn G.S., et al. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 274 (1995) 1049-1057
27. Robinson K., Gupta A., Dennis V., et al. Hyperhomocysteinemia confers an independent increased risk of atherosclerosis in end-stage renal disease and is closely linked to plasma folate and pyridoxine concentrations. Circulation 94 (1996) 2743-2748
28. Wilcken D.E., and Wilcken B. The natural history of vascular disease in homocystinuria and the effects of treatment. J Inherit Metab Dis 20 (1997) 295-300
29. Nygard O., Nordrehaug J.E., Refsum H., et al. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 337 (1997) 230-236
30. Bostom A.G., Shemin D., Verhoef P., et al. Elevated fasting total plasma homocysteine levels and cardiovascular disease outcomes in maintenance dialysis patients. A prospective study. Arterioscler Thromb Vasc Biol 17 (1997) 2554-2558
31. Brattstrom L., Zhang Y., Hurtig M., et al. A common methylenetetrahydrofolate reductase gene mutation and longevity. Atherosclerosis 141 (1998) 315-319
32. Eikelboom J.W., Lonn E., Genest Jr. J., et al. Homocyst(e)ine and cardiovascular disease: A critical review of the epidemiologic evidence. Ann Intern Med 131 (1999) 363-375
33. Toole J.F., Malinow M.R., Chambless L.E., et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: The Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA 291 (2004) 565-575
34. Bonaa K.H., Njolstad I., Ueland P.M., et al. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 354 (2006) 1578-1588
35. Lonn E., Yusuf S., Arnold M.J., et al. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 354 (2006) 1567-1577
36. Loscalzo J. Homocysteine trials-Clear outcomes for complex reasons. N Engl J Med 354 (2006) 1629-1632
37. Rozen R. Polymorphisms of folate and cobalamin metabolism. In: Carmel R., and Jacobsen D. (Eds). Homocysteine in Health and Disease (2001), Cambridge University, Cambridge, UK 259-269
38. Schneider J.A., Rees D.C., Liu Y.T., et al. Worldwide distribution of a common methylenetetrahydrofolate reductase mutation. Am J Hum Genet 62 (1998) 1258-1260
39. Stevenson R.E., Schwartz C.E., Du Y.Z., et al. Differences in methylenetetrahydrofolate reductase genotype frequencies, between whites and blacks. Am J Hum Genet 60 (1997) 229-230
40. Robinson B.M., Joffe M.M., Pisoni R.L., et al. Revisiting survival differences by race and ethnicity among hemodialysis patients: The Dialysis Outcomes and Practice Patterns Study. J Am Soc Nephrol 17 (2006) 2910-2918
41. Boger C.A., Stubanus M., Haak T., et al. Effect of MTHFR C677T genotype on survival in type 2 diabetes patients with end-stage diabetic nephropathy. Nephrol Dial Transplant 22 (2007) 154-162